Modulus Discovery, Inc., is a preclinical-stage technology-driven drug discovery firm with offices in Tokyo and Boston. The company is pursuing its proprietary portfolio of small-molecule discovery programs and collaborations through integration of its unique core biology insights, cutting-edge discovery platform, and scalable networked operations. Modulus is focused on the efficient delivery of breakthrough medicines for patients and their families with unmet medical needs in areas including oncology, chronic inflammation / immune disorders, and rare genetic conditions.
We are an international team of drug discovery scientists with extensive pharmaceutical, biotechnology, and computational research and development experience.
Our Mission and Values
Modulus is dedicated to accelerating the discovery of new medicines for patients and their families through the innovative synthesis of computational intelligence, biological inspiration, and global integration.
- Global Teamwork: We value a trusting and giving spirit in our internal and external relationships; above all, we value each other in our quest to discover new drugs.
- Open Communication: We strive to maintain clear and open communication, remove unnecessary boundaries, and share our vision, strategy, and plans with everyone on our team.
- Diversity: We respect, value, and build on each other’s unique talents and backgrounds.
- Growth Mindset: We consistently encourage and promote personal and professional growth.
- Thinking Big: We are committed to making an impact in the world by revolutionizing the way new medicines are discovered, developed, and ultimately made available to patients.
- Smart Risk-Taking: We always consider different ideas and opportunities widely, and we are not afraid to take risks, celebrate successes, and learn from mistakes.
- Focus: We strategically focus and deploy all of our resources to accelerate the discovery of new medicines and facilitate their rapid translation into the clinic
- Passion: We are passionate about helping patients and their families and making meaningful contributions to our community, our partners, and our industry.
S. Roy Kimura, Ph.D. — Cofounder & CEO
Roy has over 19 years of computational drug discovery experience, including 10 years at Bristol-Myers Squibb in Connecticut, two years at Variagenics, a personalized medicine company formerly in Cambridge, MA, and three and a half years at Schrodinger, Inc. where he was responsible for launching collaborative research projects with global pharmaceutical firms and top academic laboratories. Roy also previously served as Visiting Associate Professor at Tokyo Institute of Technology where he lectured in drug discovery and biotechnology entrepreneurship. Roy received his Ph.D. in biomedical engineering from Boston University, and completed his post-doctoral studies at MIT.
Kazuki Ohno, Dr. Eng. — Cofounder & COO
Kazuki possesses over 18 years of drug discovery experience, including 10 years as a senior researcher at Astellas Pharma. During this time, Kazuki led numerous drug discovery collaborations with academic laboratories. Kazuki also previously served as Visiting Associate Professor(Industry Youth Mentor) at Tokyo Institute of Technology. Kazuki received his Dr. Eng. From Tokyo Institute of Technology.
Yoh Terada, Ph.D. — CSO
Yoh joined Modulus in January 2018 from Astellas Pharma, where he worked for the past 18+ years in various disease biology R&D and management capacities. He most recently served as Director at Astellas Innovation Management, the innovation scouting and operations group of Astellas’ R&D department in Cambridge, MA. Prior to this, he worked at Mitobridge in Cambridge, MA where he served as the chief liaison to Astellas and established and launched their portfolio of discovery programs as Visiting Scientist, culminating in the successful closing of their recent $450M acquisition by Astellas. Throughout his career, Yoh has proposed and led over 25 discovery programs and delivered multiple IND compounds. Yoh holds a Ph.D. from Tokyo Medical and Dental University, and a B.S. from University of Tokyo.
Takahito Nakahara, Ph.D. — SVP, Business Development and Strategy
Taka joined Modulus in June 2020 from Astellas Pharma, where he played the senior positions in various departments including oncology research and clinical development, and corporate planning. He most recently served as the head at Research Program Management Office in Astellas, where all the research programs in preclinical stage to be nurtured towards early clinical trials. From 2007 to 2012, he worked at Astellas Pharma Global Development Headquarters in Chicago to lead multiple pre-PoC clinical oncology programs accompanied with development of companion diagnostics. At the corporate planning, he led numerous corporate-wide programs including new Corporate Vision, research function renovation and business area extension to non-Rx fields. Taka obtained a Ph.D. from Tokyo University of Science.
Taisuke Takahashi, Ph.D. — VP, Head of Chemistry
Taisuke joined Modulus in April 2018 from Astellas Pharma, where he worked for 13 years in R&D as Medicinal Chemist. During this time, he spent nearly three years as Visiting Scientist and liaison to Astellas Pharma at Mitobridge in Cambridge, MA, where he led multiple drug discovery programs with extensive use of global CROs. He has contributed to the delivery of multiple IND compounds. Taisuke holds a Ph.D. from Tohoku University.
|Osamu Nureki, Ph.D.||Professor, University of Tokyo||Structural Biology, Crystallography, Cryo-EM|
|Wataru Uchida, Ph.D.||Former Head of R&D, Senior Executive Board Member, Astellas Pharma||Drug Discovery Strategy|
|Yutaka Akiyama, Ph.D.||Professor, Tokyo Institute of Technology||High Performance Computing, Large-Scale GPU Computing|
|Jonathan Mason, Ph.D.||Head of CADD, Sosei Heptares, Scientific Advisor, Lundbeck||Computer-Assisted Drug Design|
|S. Roy Kimura, Ph.D.||CEO||Board Director|
|Kazuki Ohno, Dr. Eng.||COO||Board Director|
|Tomohiro Anzai, Ph.D.||Fast Track Initiative, Inc.||Board Director|
|Reiko Onodera, Ph.D.||Outside Auditor|
|Mori Naomi||Outside Auditor|
|Kohei Nakagawa||Outside Auditor|
|SMBC Venture Capital Co., Ltd.|
|Essential Pharma Co., Ltd.|
|The University of Tokyo||Tokyo Institute of Technology|